secwatch.observer — SEC 8-K summary
======================================

Issuer:     TELEFLEX INC (TFX)
CIK:        0000096943
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0000096943-25-000025
Event type: other_material
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 2.03, 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Teleflex reports Q4 adj EPS $3.89 (+15%); plans two-company split and BIOTRONIK acquisition
--------------------------------------------------------------------------------

- Q4 GAAP EPS from cont. ops. $(2.95) vs $0.66; adj EPS $3.89 vs $3.38 (+15.1%). Full-year adj EPS $14.01.
- 2025 guidance: adj EPS $13.95-$14.35; adj constant currency revenue growth 1%-2%.
- Plans tax-free separation into RemainCo (Vascular Access, Interventional, Surgical) and NewCo (Urology, Acute Care, OEM); completion expected mid-2026.
- Definitive agreement to acquire substantially all of BIOTRONIK's Vascular Intervention business; $500M delayed draw term loan facility secured.
- CFO Thomas Powell retiring Apr 1, 2025; John R. Deren succeeds as EVP & CFO effective Apr 2, consulting for one year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/96943/000009694325000025/0000096943-25-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/96943/000009694325000025/tfx-20250224.htm
  HTML page:      https://secwatch.observer/filing/0000096943-25-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer